
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 52
County: San Diego
Congr. District: 52
County: San Diego
Public Profile
FeRx is a product-oriented, targeted drug delivery company dedicated to the development and commercialization of its proprietary MTC technology to improve patient care, reduce toxicity and increase efficacy of known drugs. FeRx is completed a Phase I/II clinical trial in the U.S. of its lead compound, MTC-Doxorubicin (MTC-DOX), in patients with primary liver cancer, began a Phase II study in China during 2001, and initiated a Phase I/II study of MTC-DOX in patients with metastatic liver cancer. action.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2003 | 1 | NIH | $99,956 | |
Project Title: Magnetic Targeted Delivery of TNF Alpha and Melphalan | ||||
2003 | 2 | NIH | $739,365 | |
Project Title: Magnetic Targeting Of Radioactive Microparticles | ||||
2003 | 1 | NIH | $100,000 | |
Project Title: Targeted Delivery of Gemcitabine of Pancreatic Tumors | ||||
2001 | 1 | NIH | $99,600 | |
Project Title: GI Tract Delivery Using Magnetically Targeted Carriers |
Key People / Management
Jacqueline Johnson -- President
D Donahue
Richard Keatinge -- VP Corporate Development
Yuhua Li
Scott R Rudge -- VP Operations
D Donahue
Richard Keatinge -- VP Corporate Development
Yuhua Li
Scott R Rudge -- VP Operations
Company News
There are no news available.